Global Smart Inhaler Market was valued at US$ 1,655.2 million in 2019 and is anticipated to reach US$ 4,563.1 million by 2026 displaying an elevated CAGR of 15.7% over the forecast period (2020-2026).
Smart inhalers are the devices that are used for delivering a variety of medication through inhalation. The drugs used in the inhalers include anti-cholinergic, glucocorticoids, insulin, and beta-agonists for the treatment and prevention of respiratory diseases such as asthma and chronic obstructive pulmonary diseases. The global smart inhalers market trends have gained momentum in the healthcare industry due to cost-effectiveness and increased adherence to the treatment by patients owing to the presence of sensors attached to the inhalers, which stores data measuring the amount of dosage, increasing the efficiency of the drug. Market growth is attributed to the rapid increase in the incidence of respiratory diseases, the rise in air pollution, and growth in healthcare burden, owing to higher cases of asthma and COPD. Amongst the prevalence of COPD and asthma, COPD is expected to be the third leading cause of death globally by 2030. Better treatment options, ease of use, and technological advancements coupled with the increase in adherence rate of patients to smart inhalers are other major factors that drive this market. However, the lack of reimbursement for smart inhalers and limited availability of smart inhalers in developing regions are expected to restrain the global smart inhalers' market growth.
“Amongst product type, Inhalers dominated the global smart inhalers market, with 88.6% share and is projected to dominate the market by 2026.”
Based on product type, the report bifurcates the global smart inhalers market into Inhaler (Metered Dose Inhalers, Dry Powder Inhalers) and nebulizers. The market of metered-dose inhalers is expected to grow tremendously at a CAGR of 15.1% during the forecast period 2020-2026, due to the high adoption of these devices.
“Chronic Obstructive Pulmonary Disorder (COPD) indication segment is expected to dominate the use of smart inhalers in 2018, however Asthma indication would grow at highest CAGR growth”
Based on indication, the global smart inhaler market is segmented into Chronic Obstructive Pulmonary Disorder (COPD) and asthma. The COPD occupied the largest share and is expected to maintain its dominance throughout the forecast period 2020-2026 owing to COPD is expected to be the third leading cause of death globally by 2030. The segment generated revenue of US$ 835.5 million in 2018.
“Hospital Pharmacies was the most preferred distribution channel for smart inhalers; however, Online Pharmacies are expected to witness high adoption during the analyzed period”
On the basis of distribution channel, the report segments the global smart inhaler market into Hospital Pharmacies, Retail Pharmacies and Retail Pharmacies. In 2018, Hospital Pharmacies were the most preferred channel of distribution accounting for more than 70% share.
“Amongst end-user, Hospitals & Clinics is anticipated to dominate the Global Smart Inhaler market by 2026.”
Based on end-users the global smart inhaler market is segmented into Hospitals & Clinics, Respiratory Care Centre and others. In 2018, Hospitals & Clinics were the largest end-users of smart inhalers and is expected to remain dominance during the analysed period. However, Respiratory Care Centre are expected to witness CAGR growth of 17.7% during 2020-2026 period.
“North America represents as the largest market for smart inhaler globally, followed by Europe and Asia-Pacific”
For a deep-dive analysis of the industry, the study also includes Global regional-level analysis includes major markets of the Smart Inhaler market in North America (US, Canada, Rest of North America), Europe (Germany, UK, France, Spain, Italy and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of Asia-Pacific) and Rest of the world. In 2018, North America generated revenue of US$ 651.0 million and is expected to reach US$ 1,904.8 million by 2026. The dominance is owing to the high prevalence of respiratory disorders and rising old age population along with high awareness among the people.
Competitive Landscape-Top 10 Market Players
Boehringer Ingelheim, Cohero Health, Inc., Omron Corporation, Novartis, AstraZeneca, Teva Pharmaceuticals Industries Ltd., Vectura Group, GlaxoSmithKline, Adherium Limited, 3M are some of the prominent players operating in the Global Smart Inhaler market. Several M&A’s along with partnerships have been undertaken by these players to facilitate costumers with hi-tech and innovative products.
Global Smart Inhaler Market Segmentation
Market Insights, by Product Type
Market Insights, by Indication
Market Insights, by Distribution Channel
Market Insights, by End-User
Market Insights, by Region
Top Company Profiles
Reasons to buy:
Customization Options:
BRR understands that you may have your own business need, hence we also provide fully customized solutions to clients. The Global Smart Inhaler market can be customized to the country level or any other market segment.
1 | MARKET INTRODUCTION | |||||
1.1 | Market Definition | |||||
1.2 | Objective of the Study | |||||
1.3 | Limitation | |||||
1.4 | Stakeholders | |||||
1.5 | Currency used in the Report | |||||
1.6 | Scope of the Global Smart Inhaler Market Study | |||||
2 | RESEARCH METHODOLOGY | |||||
2.1 | Research Methodology adopted for Global Smart Inhaler Market study | |||||
2.1.1 | Main objective of the Global Smart Inhaler Market Study | |||||
3 | REGULATORY FRAMEWORK | |||||
3.1 | General Overview | |||||
3.1.1 | US Regulations for Wearable Medical Devices | |||||
3.1.1.1 | Legal Framework for Medical Device Regulation | |||||
3.1.1.2 | FDA Flexibility on Low-Risk Mobile Applications | |||||
3.1.1.3 | Legal Framework for Health Data Privacy | |||||
3.1.2 | Japan Regulations for Wearable Medical Devices | |||||
3.1.2.1 | List of software Under Regulation | |||||
3.1.2.2 | Legal Framework for Health Data Privacy | |||||
3.1.3 | European Regulations for Wearable Medical Devices | |||||
3.1.3.1 | EU Strict Rules on Medical Device Software | |||||
3.1.3.2 | Legal Framework for Health Data Privacy | |||||
4 | INDUSTRY PERFORMANCE | |||||
5 | EXECUTIVE SUMMARY | |||||
6 | MARKET OVERVIEW | |||||
6.1 | Introduction | |||||
6.2 | Market Dynamics | |||||
6.2.1 | Market Drivers | |||||
6.2.1.1 | Accelerating Geriatric Population | |||||
6.2.1.2 | Increasing Prevalence of Respiratory Disorders | |||||
6.2.1.3 | Rising Air Pollution | |||||
6.2.1.3.1 | Facts About Air Pollution: | |||||
6.2.1.4 | Rising Healthcare Expenditure and Health-Conscious Personals | |||||
6.2.1.5 | Growing Penetration of Smart Phones | |||||
6.2.2 | Market Restraints | |||||
6.2.2.1 | Overall High Cost of Inhalers | |||||
6.2.2.2 | Misusing Data and Data Privacy | |||||
6.2.2.3 | Lack of Awareness | |||||
6.2.3 | Market Trends | |||||
6.2.3.1 | Increasing demand for connected devices | |||||
6.2.3.2 | Significant Growth in IoMT Market | |||||
7 | EMERGENCE OF SMART INHALER MARKET | |||||
7.1 | General Overview | |||||
7.2 | Connected Device as a Solution | |||||
7.2.1 | Potential Benefits of Smart Inhaler | |||||
7.2.1.1 | Patients: | |||||
7.2.1.2 | Healthcare provider: | |||||
7.2.1.3 | Pharmaceutical company: | |||||
7.3 | Partnerships Between Several Pharma and Technology/ Device Companies | |||||
8 | PATIENT CONCERNS REGARDING SMART INHALERS AND CASE STUDIES | |||||
8.1 | The Survey | |||||
8.2 | Case Studies | |||||
8.2.1 | Lyndsey Affected with Poor Asthma Symptoms | |||||
8.2.2 | Jaswinder Seeking Solution for Her Daughter’s Asthma | |||||
8.2.3 | Adrian Using Connected Peak Flow for Monitoring Asthma | |||||
8.2.4 | Matthew Worrying About the Worsening of His Asthma | |||||
9 | KEY MARKET INDICATORS | |||||
9.1 | Demand Side Analysis | |||||
9.2 | Supply Side Analysis | |||||
9.2.1 | Product Launch | |||||
9.2.2 | Partnerships | |||||
9.2.3 | Business Expansion & Investments | |||||
9.2.4 | Merger and Acquisitions | |||||
9.3 | Value Chain Analysis of Smart Inhaler Market | |||||
10 | MARKET INSIGHTS BY PRODUCT | |||||
10.1 | General Overview | |||||
10.1.1 | Inhalers | |||||
10.1.1.1 | Dry Powder Inhaler (DPI) | |||||
10.1.1.2 | Metered Dose Inhaler (MDI) | |||||
10.1.2 | Nebulizers | |||||
11 | MARKET INSIGHTS BY INDICATION | |||||
11.1 | General Overview | |||||
11.1.1 | Chronic Obstructive Pulmonary Disease (COPD) | |||||
11.1.2 | Asthma | |||||
12 | MARKET INSIGHTS BY DISTRIBUTION CHANNEL | |||||
12.1 | General Overview | |||||
12.1.1 | Hospital Pharmacies | |||||
12.1.2 | Retail Pharmacies | |||||
12.1.3 | Online Channel | |||||
13 | MARKET INSIGHTS, BY END-USER | |||||
13.1 | General Overview | |||||
13.1.1 | Hospitals & Clinics | |||||
13.1.2 | Respiratory Care Centre | |||||
13.1.3 | Others | |||||
14 | MARKET INSIGHTS BY REGION/COUNTRY | |||||
14.1 | General Overview | |||||
14.2 | North America Smart Inhaler Market | |||||
14.2.1 | North America Smart Inhalers Market, by Product | |||||
14.2.2 | North America Smart Inhalers Market, by Indication | |||||
14.2.3 | North America Smart Inhalers Market, by Distribution Channel | |||||
14.2.4 | North America Smart Inhalers Market, by End-Users | |||||
14.2.5 | North America Smart Inhalers Market, by Country | |||||
14.2.5.1 | United States Smart Inhaler Market | |||||
14.2.5.1.1 | Key Findings on Healthcare Spending in the US, 2017 | |||||
14.2.5.1.2 | US Health Spending by Type of Service or Product, 2017 | |||||
14.2.5.1.3 | Health Spending by Major Sources of Funds | |||||
14.2.5.1.4 | US Smart Inhalers Market, by Product | |||||
14.2.5.1.5 | US Smart Inhalers Market, by Indication | |||||
14.2.5.1.6 | US Smart Inhalers Market, by Distribution Channel | |||||
14.2.5.1.7 | US Smart Inhalers Market, by End-Users | |||||
14.2.5.2 | Canada Smart Inhaler Market | |||||
14.2.5.2.1 | Key Facts on Total Hospital Cost, by Health Conditions Canada, 2016 | |||||
14.2.5.2.2 | Key Findings on Canada Healthcare Spending, 2018 | |||||
14.2.5.2.3 | Key Findings on Hospital sector Spending in Canada, 2018 | |||||
14.2.5.2.4 | Canada Smart Inhalers Market, by Product | |||||
14.2.5.2.5 | Canada Smart Inhalers Market, by Indication | |||||
14.2.5.2.6 | Canada Smart Inhalers Market, by Distribution Channel | |||||
14.2.5.2.7 | Canada Smart Inhalers Market, by End-Users | |||||
14.2.5.3 | Rest of the NA Smart Inhaler Market | |||||
14.2.5.3.1 | Key Findings on Healthcare Spending in Mexico, 2016 | |||||
14.2.5.3.2 | Rest of NA Smart Inhalers Market, by Product | |||||
14.2.5.3.3 | Rest of NA Smart Inhalers Market, by Indication | |||||
14.2.5.3.4 | Rest of NA Smart Inhalers Market, by Distribution Channel | |||||
14.2.5.3.5 | Rest of NA Smart Inhalers Market, by End-Users | |||||
14.3 | Europe Smart Inhaler Market | |||||
14.3.1 | Europe Smart Inhalers Market, by Product | |||||
14.3.2 | Europe Smart Inhalers Market, by Indication | |||||
14.3.3 | Europe Smart Inhalers Market, by Distribution Channel | |||||
14.3.4 | Europe Smart Inhalers Market, by End-Users | |||||
14.3.5 | Europe Smart Inhalers Market, by Country | |||||
14.3.5.1 | Germany Smart Inhaler Market | |||||
14.3.5.1.1 | Facts on COPD and Asthma in Germany | |||||
14.3.5.1.2 | Germany Smart Inhalers Market, by Product | |||||
14.3.5.1.3 | Germany Smart Inhalers Market, by Indication | |||||
14.3.5.1.4 | Germany Smart Inhalers Market, by Distribution Channel | |||||
14.3.5.1.5 | Germany Smart Inhalers Market, by End-Users | |||||
14.3.5.2 | United Kingdom Smart Inhaler Market | |||||
14.3.5.2.1 | United Kingdom Smart Inhalers Market, by Product | |||||
14.3.5.2.2 | United Kingdom Smart Inhalers Market, by Indication | |||||
14.3.5.2.3 | United Kingdom Smart Inhalers Market, by Distribution Channel | |||||
14.3.5.2.4 | United Kingdom Smart Inhalers Market, by End-Users | |||||
14.3.5.3 | Spain Smart Inhaler Market | |||||
14.3.5.3.1 | Spain Smart Inhalers Market, by Product | |||||
14.3.5.3.2 | Spain Smart Inhalers Market, by Indication | |||||
14.3.5.3.3 | Spain Smart Inhalers Market, by Distribution Channel | |||||
14.3.5.3.4 | Spain Smart Inhalers Market, by End-Users | |||||
14.3.5.4 | France Smart Inhaler Market | |||||
14.3.5.4.1 | France Smart Inhalers Market, by Product | |||||
14.3.5.4.2 | France Smart Inhalers Market, by Indication | |||||
14.3.5.4.3 | France Smart Inhalers Market, by Distribution Channel | |||||
14.3.5.4.4 | France Smart Inhalers Market, by End-Users | |||||
14.3.5.5 | Italy Smart Inhaler Market | |||||
14.3.5.5.1 | Italy Smart Inhalers Market, by Product | |||||
14.3.5.5.2 | Italy Smart Inhalers Market, by Indication | |||||
14.3.5.5.3 | Italy Smart Inhalers Market, by Distribution Channel | |||||
14.3.5.5.4 | Italy Smart Inhalers Market, by End-Users | |||||
14.3.5.6 | Rest of Europe Smart Inhaler Market | |||||
14.3.5.6.1 | Rest of Europe Smart Inhalers Market, by Product | |||||
14.3.5.6.2 | Rest of Europe Smart Inhalers Market, by Indication | |||||
14.3.5.6.3 | Rest of Europe Smart Inhalers Market, by Distribution Channel | |||||
14.3.5.6.4 | Rest of Europe Smart Inhalers Market, by End-Users | |||||
14.4 | Asia-Pacific Smart Inhaler Market | |||||
14.4.1 | Asia-Pacific Smart Inhalers Market, by Product | |||||
14.4.2 | Asia-Pacific Smart Inhalers Market, by Indication | |||||
14.4.3 | Asia-Pacific Smart Inhalers Market, by Distribution Channel | |||||
14.4.4 | Asia-Pacific Smart Inhalers Market, by End-Users | |||||
14.4.5 | Asia-Pacific Smart Inhalers Market, by Country | |||||
14.4.5.1 | China Smart Inhaler Market | |||||
14.4.5.1.1 | China Smart Inhalers Market, by Product | |||||
14.4.5.1.2 | China Smart Inhalers Market, by Indication | |||||
14.4.5.1.3 | China Smart Inhalers Market, by Distribution Channel | |||||
14.4.5.1.4 | China Smart Inhalers Market, by End-Users | |||||
14.4.5.2 | India Smart Inhaler Market | |||||
14.4.5.2.1 | India Smart Inhalers Market, by Product | |||||
14.4.5.2.2 | India Smart Inhalers Market, by Indication | |||||
14.4.5.2.3 | India Smart Inhalers Market, by Distribution Channel | |||||
14.4.5.2.4 | India Smart Inhalers Market, by End-Users | |||||
14.4.5.3 | Japan Smart Inhaler Market | |||||
14.4.5.3.1 | Changing Demographic Structure of Japan | |||||
14.4.5.3.2 | Japan Smart Inhalers Market, by Product | |||||
14.4.5.3.3 | Japan Smart Inhalers Market, by Indication | |||||
14.4.5.3.4 | Japan Smart Inhalers Market, by Distribution Channel | |||||
14.4.5.3.5 | Japan Smart Inhalers Market, by End-Users | |||||
14.4.5.4 | Australia Smart Inhaler Market (2018-2025) | |||||
14.4.5.4.1 | Australia Smart Inhalers Market, by Product | |||||
14.4.5.4.2 | Australia Smart Inhalers Market, by Indication | |||||
14.4.5.4.3 | Australia Smart Inhalers Market, by Distribution Channel | |||||
14.4.5.4.4 | Australia Smart Inhalers Market, by End-Users | |||||
14.4.5.5 | South Korea Smart Inhaler Market | |||||
14.4.5.5.1 | South Korea Smart Inhalers Market, by Product | |||||
14.4.5.5.2 | South Korea Smart Inhalers Market, by Indication | |||||
14.4.5.5.3 | South Korea Smart Inhalers Market, by Distribution Channel | |||||
14.4.5.5.4 | South Korea Smart Inhalers Market, by End-Users | |||||
14.4.5.6 | Rest of Asia-Pacific Smart Inhaler Market (2018-2025) | |||||
14.4.5.6.1 | Rest of APAC Smart Inhalers Market, by Product | |||||
14.4.5.6.2 | Rest of APAC Smart Inhalers Market, by Indication | |||||
14.4.5.6.3 | Rest of APAC Smart Inhalers Market, by Distribution Channel | |||||
14.4.5.6.4 | Rest of APAC Smart Inhalers Market, by End-Users | |||||
14.5 | Rest of World Smart Inhaler Market (2018-2025) | |||||
14.5.1 | Rest of World Smart Inhalers Market, by Product | |||||
14.5.2 | Rest of World Smart Inhalers Market, by Indication | |||||
14.5.3 | Rest of World Smart Inhalers Market, by Distribution Channel | |||||
14.5.4 | Rest of World Smart Inhalers Market, by End-Users | |||||
15 | COMPETITIVE SCENARIO | |||||
15.1 | Porter’s Five forces analysis | |||||
15.1.1 | Bargaining Power of Buyers | |||||
15.1.2 | Bargaining power of Supplier | |||||
15.1.3 | Threat of new entrants | |||||
15.1.4 | Availability of Substitute | |||||
15.1.5 | Industry Rivalry | |||||
15.3 | Market Share Analysis, by Company 2019 | |||||
16 | TOP COMPANY PROFILES | |||||
16.1 | Boehringer Ingelheim | |||||
16.1.1 | Key Facts | |||||
16.1.2 | Business Description | |||||
16.1.3 | Key Product/Services Offerings | |||||
16.1.4 | Growth Strategy | |||||
16.1.5 | SWOT Analysis | |||||
16.1.6 | Key Financials (2014-2018) | |||||
16.1.7 | Revenue Split | |||||
16.1.8 | Recent Developments | |||||
16.1.8.1 | Product Launches | |||||
16.1.8.2 | Business Expansion and Investments | |||||
16.2 | Cohero Health, Inc. | |||||
16.2.1 | Key Facts | |||||
16.2.2 | Business Description | |||||
16.2.3 | Key Product/Services Offerings | |||||
16.2.4 | Growth Strategy | |||||
16.2.5 | SWOT Analysis | |||||
16.2.6 | Recent Developments | |||||
16.2.6.1 | Product Launches | |||||
16.2.6.2 | Investment | |||||
16.3 | Omron Corporation | |||||
16.3.1 | Key Facts | |||||
16.3.2 | Business Description | |||||
16.3.3 | Key Product/Services Offerings | |||||
16.3.4 | Growth Strategy | |||||
16.3.5 | SWOT Analysis | |||||
16.3.6 | Key Financials (2014-2018) | |||||
16.3.7 | Revenue Split | |||||
16.4 | Novartis | |||||
16.4.1 | Key Facts | |||||
16.4.2 | Business Description | |||||
16.4.3 | Key Product/Services Offerings | |||||
16.4.4 | Growth Strategy | |||||
16.4.5 | SWOT Analysis | |||||
16.4.6 | Key Financials (2014-2018) | |||||
16.4.7 | Revenue Split | |||||
16.5 | AstraZeneca | |||||
16.5.1 | Key Facts | |||||
16.5.2 | Business Description | |||||
16.5.3 | Key Product/Services Offerings | |||||
16.5.4 | Growth Strategy | |||||
16.5.5 | SWOT Analysis | |||||
16.5.6 | Key Financials | |||||
16.5.7 | Revenue Split | |||||
16.5.8 | Recent Developments | |||||
16.5.8.1 | Product Launches | |||||
16.5.8.2 | Business Expansion | |||||
16.6 | Teva Pharmaceuticals Industries Ltd. | |||||
16.6.1 | Key Facts | |||||
16.6.2 | Business Description | |||||
16.6.3 | Key Product/Services Offerings | |||||
16.6.4 | Growth Strategy | |||||
16.6.5 | SWOT Analysis | |||||
16.6.6 | Key Financials (2014-2018) | |||||
16.6.7 | Revenue Split | |||||
16.6.8 | Recent Developments | |||||
16.6.8.1 | Product Launch | |||||
16.6.8.2 | Business Expansion | |||||
16.7 | Vectura Group | |||||
16.7.1 | Key Facts | |||||
16.7.2 | Business Description | |||||
16.7.3 | Key Product/Services Offerings | |||||
16.7.4 | Growth Strategy | |||||
16.7.5 | SWOT Analysis | |||||
16.7.6 | Key Financials | |||||
16.7.7 | Revenue Split | |||||
16.7.8 | Recent Developments | |||||
16.7.8.1 | Product Launches | |||||
16.7.8.2 | Partnership | |||||
16.8 | GlaxoSmithKline | |||||
16.8.1 | Key Facts | |||||
16.8.2 | Business Description | |||||
16.8.3 | Key Product/Services Offerings | |||||
16.8.4 | Growth Strategy | |||||
16.8.5 | SWOT Analysis | |||||
16.8.6 | Key Financials | |||||
16.8.7 | Revenue Split | |||||
16.8.8 | Recent Developments | |||||
16.8.8.1 | Product Launches | |||||
16.8.8.2 | Merger and Acquisitions | |||||
16.9 | Adherium Limited | |||||
16.9.1 | Key Facts | |||||
16.9.2 | Business Description | |||||
16.9.3 | Key Product/Services Offerings | |||||
16.9.4 | Growth Strategy | |||||
16.9.5 | SWOT Analysis | |||||
16.9.6 | Key Financials (2014-2018) | |||||
16.9.6.1 | Revenue Split | |||||
16.9.7 | Recent Developments | |||||
16.9.7.1 | Product Launches | |||||
16.9.7.2 | Partnership | |||||
16.1 | 3M | |||||
16.10.1 | Key Facts | |||||
16.10.2 | Business Description | |||||
16.10.3 | Key Product/Services Offerings | |||||
16.10.4 | SWOT Analysis | |||||
16.10.5 | Key Financials | |||||
16.10.6 | Revenue Split | |||||
16.10.7 | Recent Developments | |||||
16.10.7.1 | Product Launches |
According to Business Research Reports, Global In-Store Analytics Market was valued at USD 941 Million in 2018 and is projected to reach USD 4,252.1 Million by 2026, growing at a CAGR of 20.64% from 2019 to 2026.
February 2020 | Price: $3950
According to Business Research Reports, Global Intelligent PDU Market was valued at USD 1.32 Billion in 2018 and is projected to reach USD 2.48 Billion by 2026, growing at a CAGR of 8.12% from 2019 to 2026.
February 2020 | Price: $3950
According to Business Research Reports, Middle East & Africa Cybersecurity Market was valued at USD 5.92 Billion in 2018 and is projected to reach USD 17.30 Billion by 2026, growing at a CAGR of 14.35% from 2019 to 2026.
February 2020 | Price: $3950